Espionage
发表于 2025-3-21 18:03:35
书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0876358<br><br> <br><br>书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0876358<br><br> <br><br>书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0876358<br><br> <br><br>书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0876358<br><br> <br><br>书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0876358<br><br> <br><br>书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0876358<br><br> <br><br>书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0876358<br><br> <br><br>书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0876358<br><br> <br><br>书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0876358<br><br> <br><br>书目名称Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0876358<br><br> <br><br>
TRACE
发表于 2025-3-21 20:25:19
Sample Size Allocation in a Dose-Ranging Trial Combined with PoCand ethical concerns may limit the total sample size for the trial. This manuscript discusses various ways of allocating the sample size to each treatment group, under a given total sample size; as well as the performance of different contrast test for PoC.
labile
发表于 2025-3-22 04:01:06
http://reply.papertrans.cn/88/8764/876358/876358_3.png
Infant
发表于 2025-3-22 06:29:35
2199-0980analysis. Each papers was peer-reviewed by at least two referees and also by an editor. The conference was attended by over 400 participants from academia, industry, and government agencies around the world, including from North America, Asia, and Europe..978-3-319-82610-3978-3-319-42568-9Series ISSN 2199-0980 Series E-ISSN 2199-0999
hysterectomy
发表于 2025-3-22 11:21:40
Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkersizes the overall response rate for all the patients enrolled in the trial. We develop a likelihood ratio test to evaluate the subgroup treatment effects at the end of the trial. Simulation studies show that the proposed optimal designs achieve our design goal and obtain desirable operating characteristics.
碎片
发表于 2025-3-22 14:53:12
http://reply.papertrans.cn/88/8764/876358/876358_6.png
NOTCH
发表于 2025-3-22 20:36:16
Bayesian Integration of In Vitro Biomarker to Analysis of In Vivo Safety Assessmentn animal studies. In this chapter, we extend on the previous work by Chiang and Wang (Stat Biopharm Res 7:66–75, 2015) to further investigate how in vitro data can be integrated by the proposed approach and how decisions concerning QT prolongation can be more informatively made for drugs moving from pre-clinical to clinical evaluation.
无法取消
发表于 2025-3-22 21:33:22
Personalized Effective Dose Selection in Dose Ranging Studieswill be useful for identifying the respondent subgroups and their accompanying doses for the future study design. We illustrate the proposed method with simulation studies. Our method compares favorably to two ad-hoc approaches.
Germinate
发表于 2025-3-23 02:06:02
Assessing Benefit and Consistency of Treatment Effect Under a Discrete Random Effects Model in Multinder DREM, we consider the concept of the Method 2 in “Basic Principles on Global Clinical Trials” guidance to construct the probability function of benefit and consistency. We also optimize the sample size allocation to reach maximum power for the benefit and consistency.
保守党
发表于 2025-3-23 07:21:33
http://reply.papertrans.cn/88/8764/876358/876358_10.png